What factors affect the duration of treatment with diphenylcyclopropenone immunotherapy for common warts?

Seo, Hyun-Min; Park, Hyung Kwon; Kim, Tae Lim; Kim, Joung Soo

doi:10.1111/dth.12740

Cited by 1 publication

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To initiate contact immunotherapy, the patients first received the contact allergen topically at a concentration much higher than that actually used during subsequent treatment with gradual up-titration. Traditionally, a stronger inflammatory reaction was linked to a higher chance of treatment success, since the strong reaction indicates stronger stimulation of the immune system [ 21 , 22 ]. However, some research did not show a correlation between the inflammatory reaction and the therapeutic results [ 23 , 24 ].…”

Section: The Relationship Between Sensitization and Prognosismentioning

confidence: 99%

“…In 1973, the first use of DNCB contact immunotherapy for resistant warts was reported with a cure rate of 91% [ 28 ]. Thereafter, numerous reports using DNCB, DPCP, and SADBE were published [ 1 , 16 , 21 , 22 , 24 , 28 – 74 ]. Now, contact immunotherapy plays an important role in treating warts, when other options such as chemical destruction (salicylic acid and/or lactic acid topical paints) or physical destruction (liquid nitrogen cryotherapy) show unfavorable results [ 1 ].…”

Section: Topical Immunotherapy In the Treatment Of Skin Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

Use of Contact Immunotherapy in the Treatment of Skin Diseases Other than Alopecia Areata

Lai

Tsai

2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

For decades, contact immunotherapy with dinitrochlorobenzene, diphencyprone, and squaric acid dibutylester has played an important role in both clinical practice and scientific research. It is listed as the first-line treatment for extensive alopecia areata and was more recently approved for melanoma treatment as an orphan drug in the USA. Moreover, owing to the relative low cost and safety, topical immunotherapy has also been used in many infectious, neoplastic, and inflammatory dermatological diseases. It is especially valuable in vulnerable groups, for cosmetic/pain sensitive areas, or for multiple lesions. In this review, we summarize the current evidence supporting the use of contact immunotherapy for treatment of skin diseases, from articles collected from PubMed database. Owing to space limitation and already numerous studies focusing on alopecia areata, we include only skin diseases other than alopecia areata. In addition to diseases that have been reported to be treated by contact immunotherapy, the hypothesized mechanism, prognosis prediction, efficacy, and safety of these topical agents are discussed.

show abstract